A Nurses’ Perspective: Oral Therapies in Breast Cancer: Considerations for Enhanced Adherence in the Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2-negative Breast Cancer
FACULTY
Sramila Aithal, MD
Breast Oncologist/Hematologist
Alliance Cancer Specialists
US Oncology Network
Philadelphia, PA
Evelyn Robles-Rodríguez, DNP, APN, AOCN
Director, Outreach, Prevention and Survivorship
MD Anderson Cancer Center at Cooper
Camden, New Jersey
PROGRAM OVERVIEW
Oncology nurses are in an inherently valuable position to be in the frontline of breast cancer treatment for patients. Given identified gaps and faculty feedback, the instructional design of this program is a multi-pronged educational approach designed for an oncology nursing audience.
TARGET AUDIENCE
This activity is intended for frontline US-based oncology nurses, oncologists, advanced practice clinicians, and pharmacists caring for patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer.
LEARNING OBJECTIVES
- Evaluate patient education strategies to enhance adherence and persistence to treatment with oral oncolytic therapies in the setting of HR+/HER2- BC
- Discuss the importance of side effect monitoring, recognition, management, and patient education in enhancing patient quality of life and treatment persistence in HR+/HER2- BC treated with oral oncolytics
- Optimize nursing strategies for optimal communication, patient care coordination, and multidisciplinary care team collaboration
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
This CME activity was planned and produced in accordance with the ACCME Essentials.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in caring for patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer.
CNE Credits: 1.5 ANCC Contact Hours.
CNE ACCREDITATION STATEMENT
Ultimate Medical Academy/CCM is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 1.5 contact hours of continuing nursing education of RNs and APNs.
ONCC STATEMENT
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturers of any commercial products and/or providers of commercial services that are discussed in an educational activity.
DISCLOSURE OF CONFLICTS OF INTEREST
Sramila Aithal MD, discloses she is on the on the speakers’ bureau for Pfizer, Seagen, Daichii/Astrazeneca and Merck.
Evelyn Robles-Rodríguez, DNP, APN, AOCN discloses that she has received a research grant from Genentech and Pfizer.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
Joan Duer-Hefele, RN, MA, CCRC
The reviewer of this activity has nothing to disclose.
Staff Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
- Matthew Frese, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
- Dave Chatman, Medical Director of Med Learning Group, has nothing to disclose.
- Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to disclose.
- Jessica Feygin, Program Coordinator of Med Learning Group, has nothing to disclose.
- Joan Duer-Hefele, RN, MA, CCRC, has nothing to disclose.
- Lauren Welch, MA, VP of Accreditation and Outcomes of Med Learning Group, has nothing to disclose.
- Aimee Meissner, Accreditation and Outcomes Coordinator of Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME/CE credit for this enduring activity. To receive CME/CE credit participants must:
- Read the CME/CNE information and faculty disclosures.
- Participate in the enduring activity.
- Submit the evaluation form to Med Learning Group.
You will receive your certificate upon completion as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at info@medlearninggroup.com
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com
RELEASE DATE: April 29, 2022
EXPIRATION DATE: April 29, 2023
Copyright © 2022 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
